Financial Performance - Revenue for Q4 2025 grew 7% year-over-year to $12.21 billion, while full-year revenue increased 4% to $44.56 billion [7][8] - Adjusted operating income for Q4 rose 6% to $2.88 billion, and for the full year, it grew 4% to $10.11 billion [8][27] - Adjusted EPS for Q4 increased 8% to $6.57, and for the full year, it grew 5% to $22.87 [8][26] - Adjusted operating margin for Q4 was 23.6%, and for the full year, it was 22.7% [8][28] Business Segment Performance - Life Science Solutions reported revenue growth of 13% in Q4 and 8% for the full year, driven by strong bioproduction performance [32] - Analytical Instruments saw a 1% increase in revenue for both Q4 and the full year, with adjusted operating income decreasing 12% in Q4 [33] - Specialty Diagnostics reported a 5% revenue increase in Q4 and a 4% increase for the full year, with adjusted operating income up 19% in Q4 [34] - Laboratory Products and Biopharma Services experienced a 7% revenue increase in Q4 and a 4% increase for the full year [35] Market Performance - North America and Asia Pacific grew low single digits in Q4, while Europe grew mid-single digits [27] - China experienced a low single-digit decline for both Q4 and the full year [27] Company Strategy and Competitive Position - The company’s growth strategy focuses on high-impact innovation, trusted partnerships, and a strong commercial engine [10][11] - Significant advancements in innovation were highlighted, including new product launches in chromatography, bioproduction, and clinical diagnostics [11][12][13] - Strategic partnerships, including collaborations with the Chan Zuckerberg Institute and OpenAI, were emphasized to enhance capabilities and productivity [16] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in entering 2026 from a position of strength, with expectations of continued share gain and operational excellence [6][24] - The guidance for 2026 includes revenue expectations of $46.3 billion to $47.2 billion, representing 4%-6% growth, and adjusted EPS guidance of $24.22 to $24.80, indicating 6%-8% growth [23][36] Other Important Information - The company deployed approximately $16.5 billion in 2025, including $13 billion for M&A and $3.6 billion returned to shareholders [17][30] - The acquisition of Clario, expected to close by mid-2026, is anticipated to be accretive to adjusted EPS by approximately $0.45 in the first year [19][38] Q&A Session Summary Question: Insights on the guidance and market conditions - Management indicated that the guidance assumes market conditions similar to 2025, with expectations of organic growth in the 3%-4% range [51][52] Question: Sentiment on biopharma spending - Management noted improved sentiment in biopharma spending, with indications of better budgets for 2026 [60][61] Question: Industry supply and demand dynamics in pharma services - Management highlighted strong demand in sterile fill finish and the strategic acquisition of a site to expand capacity [66][67] Question: Competitive dynamics in the channel business - Management stated that competitive dynamics remain stable, with a consistent share gain over the years [69][70] Question: Impact of ecosystem changes on customer preferences - Management discussed the positive impact of the Accelerator offering and collaboration with OpenAI to enhance drug development efficiency [78][79]

Financial Data and Key Metrics Changes - Revenue for Q2 grew 3% to $10.85 billion, with adjusted operating income increasing 1% to $2.38 billion [6][28] - Adjusted operating margin was 21.9%, and adjusted EPS was $5.36 per share, exceeding guidance [7][26] - Free cash flow was $1.5 billion after $645 million in net capital expenditures, with cash and short-term investments totaling $6.4 billion [30][31] Performance by Business Segment - Life Science Solutions reported a 6% increase in revenue, with organic growth of 4%, driven by bioproduction [32] - Analytical Instruments saw a 3% decline in reported revenue, with organic growth down 4%, primarily due to tariffs and muted demand [34] - Specialty Diagnostics revenue grew 2% year-over-year, with adjusted operating margin at 27% [35] - Laboratory Products and Biopharma Services segment reported a 4% increase in revenue, with organic growth of 3% [36] Market Data and Key Metrics Changes - North America and Europe experienced low single-digit growth, while Asia Pacific declined low single digits, with China seeing a high single-digit decline [27] - The academic and government market faced mid-single-digit revenue decline due to customer hesitancy [9] Company Strategy and Industry Competition - The company focuses on high-impact innovation, trusted partner status, and a strong commercial engine to drive growth [10][12] - Recent product launches include advanced mass spectrometers and a cryo transmission electron microscope, enhancing competitive positioning [11] - The company is actively managing costs and navigating tariff impacts through its PPI business system [18][39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in long-term growth drivers, expecting organic revenue growth of 3% to 6% in 2026 and 2027 [21][23] - The company anticipates a gradual improvement in end markets, particularly in pharma and biotech, with a focus on customer collaboration [20][22] - Management highlighted the importance of maintaining strong relationships with customers to navigate current challenges [12][71] Other Important Information - The CFO announced plans to retire in March 2026, with a transition to the current VP of Financial Operations [46][48] - The company is on track to close the acquisition of Silventum's purification and filtration business by year-end [16][19] Q&A Session Summary Question: What is the long-term growth outlook? - Management expects a long-term organic revenue growth of 7% plus, driven by strong industry fundamentals and share gains [54][59] Question: How will margin expansion be achieved? - Margin expansion of 50 to 70 basis points is expected, leveraging existing tools and PPI capabilities [60][63] Question: How is the biopharma sector responding to macro factors? - The biopharma sector shows broad strength, with strong growth in bioproduction and pharma services despite macro challenges [67][70] Question: What is the outlook for the Analytical Instruments business? - The Analytical Instruments segment is impacted by muted conditions in academic and government sectors, but new product launches are expected to drive share gains [73][81] Question: How is the company managing customer purchasing decisions amid reshoring? - There is heightened interest in expanding US manufacturing capacity, and customers are not pausing purchases in bioproduction [78][80] Question: What is the funding outlook for academic and government sectors? - There is bipartisan support for funding in life sciences, and budgets are expected to stabilize, moving from a headwind to growth [89][94]